HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.

Br J Cancer · 2005 · PMC2361531 · PMID 16288303

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Combining the EGFR and HER3 gene status determined by FISH, we observed that patients positive for both receptors (EGFR+/HER3+) had a significantly higher response and longer TTP, with a nonsignificant trend toward longer survival.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.